Satellos Bioscience Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Satellos Bioscience
Pharmaceutical Preparations, SIC 2834
Satellos Bioscience Inc. is a Canada-based biotechnology corporation that focuses on the research and development of pharmaceutical products and therapeutic treatments. The company's activities primarily center on developing proprietary drug candidates and advancing licensed medical products through clinical trials, regulatory submissions, and potential commercialization. Operating as a single primary segment in drug research and development, its business initiatives and therapies are aimed at treating patients and serving stakeholders within the broader healthcare and biopharmaceutical industry.
The company maintains operational presence across Canada, the United States, and Australia. Its corporate headquarters and principal executive offices are situated in Toronto, Ontario, Canada, with additional administrative facilities and an agent for service located in Boston, Massachusetts, United States. Satellos conducts its clinical trial, developmental, and corporate activities under Canadian and U.S. regulatory oversight while managing international research commitments.
Summary of the business section of Satellos Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Satellos Bioscience Inc.
- Headquarters
- Markham, Ontario, Canada
- Address
- 15 Allstate Parkway, Suite 600 L3R 5B4
- Phone
- (647) 660-1780
- Website
- satellos.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Z4
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Toronto, Canada
Stock & identifiers
- Ticker
- MSLE
- Exchange
- Nasdaq
- Shares outstanding
- 15M, Dec 31, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-12 reverse, Jan 30, 2026; 1-for-20 reverse, Aug 18, 2021
- SEC CIK
- 1421642
- CUSIP
- 80401L803
- ISIN
- US80401L8037
- LEI
- 529900EN243BZ5QC9N39
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Satellos Bioscience's leadership is listed in its proxy statement (Form DEF 14A).
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 5, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 10, 2019 | Name change | Name changed from ICO THERAPEUTICS INC to Satellos Bioscience Inc. |